Boston Private Bank & Trust’s Myriad Genetics MYGN Stock Holding History

Boston Private Bank & Trust’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$18K	Hold	500	–	–	﹤0.01%	749
2014 Q4	$17K	Hold	500	–	–	﹤0.01%	780
2014 Q3	$19K	Hold	500	–	–	﹤0.01%	776
2014 Q2	$19K	Hold	500	–	–	﹤0.01%	751
2014 Q1	$17K	Hold	500	–	–	﹤0.01%	773
2013 Q4	$10K	Hold	500	–	–	﹤0.01%	845
2013 Q3	$12K	Hold	500	–	–	﹤0.01%	787
2013 Q2	$13K	Buy	+500	New	+$14.5K	﹤0.01%	740

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Boston Private Bank & Trust's MYGN Position: Q1 2015 in Review

Boston Private Bank & Trust held its Myriad Genetics (MYGN) position steady in Q1 2015 at 500 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #749.

Boston Private Bank & Trust first reported a position in MYGN in Q2 2013 and has held it in 8 quarters since. The position peaked at $19K in Q3 2014. 252 funds tracked by Wall St. Rank hold MYGN as of Q1 2015.

Boston Private Bank & Trust held 500 shares of Myriad Genetics worth $18K as of Q1 2015.
Boston Private Bank & Trust left its Myriad Genetics share count unchanged in Q1 2015.
Myriad Genetics made up ﹤0.01% of Boston Private Bank & Trust's portfolio in Q1 2015, its #749 holding.
Boston Private Bank & Trust first reported a position in Myriad Genetics in Q2 2013 and has held it in 8 quarters since.
Boston Private Bank & Trust's Myriad Genetics position peaked at $19K in Q3 2014.
252 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2015.

Based on Boston Private Bank & Trust's 13F filing for Q1 2015, filed 9 Apr 2015.